[Clinical usefulness of eticholanolone in the evaluation of bone marrow reserves in patients treated with myelosuppressive drugs and with radiotherapy].
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D001854:Bone Marrow Cells; D001855:Bone Marrow Diseases / Q000188:drug therapy; D001856:Bone Marrow Examination; D002066:Busulfan / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003348:Cortisone / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005043:Etiocholanolone; D005260:Female; D006402:Hematologic Diseases / Q000628:therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007958:Leukocyte Count; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D011830:Radiation Effects; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D002699:Chlorambucil; D014747:Vinblastine; D005043:Etiocholanolone; D015122:Mercaptopurine; D002066:Busulfan; D003348:Cortisone; D003630:Daunorubicin
Utilità clinica dell'uso dell'etiocolanolone nella valutazione della riserva midollare in pazienti trattati con farmaci mielosoppressivi e con terapia radiante.